Stock INNO INNOCAN PHARMA CORPORATION
Add to a list
To use this feature you must be a member
Log inSign up

InnoCan Pharma Corporation

Equities

INNO

CA45783P1027

Pharmaceuticals

Delayed Canadian Securities Exchange
Other stock markets
 12:16:48 2024-12-10 pm EST 		5-day change 1st Jan Change
0.2200 CAD +10.00% Intraday chart for InnoCan Pharma Corporation -4.65% -33.87%
Nov. 26 InnoCan Pharma Releases Encouraging Results from Study of LPT-CBD on Minipigs MT
Nov. 26 Innocan Pharma Corporation Announces Encouraging Results from a Safety Assessment Study of LPT-CBD on Minipigs CI
LockThis article is reserved for members
To unlock the article, REGISTER!
Already a customer? Log In

Latest news about InnoCan Pharma Corporation

InnoCan Pharma Releases Encouraging Results from Study of LPT-CBD on Minipigs Nov. 26 MT
Innocan Pharma Corporation Announces Encouraging Results from a Safety Assessment Study of LPT-CBD on Minipigs Nov. 26 CI
InnoCan Pharma Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 Nov. 20 CI
InnoCan Pharma Swings to a Q3 Profit on Revenue Gains Nov. 20 MT
Innocan Pharma's LPT-CBD Shows Success in Relieving Osteoarthritis Pain in Dogs Oct. 11 MT
Innocan Pharma Corporation's LPT-CBD Shows Long-Term Success in Relieving Osteoarthritis Pain in Dogs Oct. 11 CI
Innocan Says FDA "Positive" on it Liposomal Technology-CBD Drug Sep. 03 MT
Innocan Pharma Corporation Advances Liposomal CBD with Positive Response from FDA Following Successful Pre-IND Meeting Sep. 03 CI
InnoCan Pharma Corporation announced that it has received CAD 1.10566 million in funding Aug. 28 CI
InnoCan Pharma Corporation announced that it expects to receive CAD 0.88 million in funding Aug. 21 CI
InnoCan Pharma Corporation Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2024 Aug. 12 CI
Innocan Pharma Submits Investigational New Animal Drug Application to FDA's Veterinary Center Jul. 26 MT
Innocan Pharma Corporation Submits Investigational New Animal Drug Application to FDA's Veterinary Center Jul. 26 CI
Innocan Pharma Engages Pain-Management Expert Ahead of FDA Meeting Jul. 02 MT
Innocan Pharma Announces Successful Preliminary Safety Evaluation of LPT-CBD in Minipigs Jun. 11 MT
InnoCan Pharma Corporation Reports Earnings Results for the First Quarter Ended March 31, 2024 May. 27 CI
Innocan Pharma Reports First Quarter 2024 Results With Revenue Growth Of Over 4X To $6.8 Million May. 27 MT
Refile: FDA Has Granted Innocan Pharma a Meeting Date for LPT-CBD for Chronic Pain May. 21 MT
InnoCan Pharma Brief: FDA Has Granted Innocan Pharma a Meeting Date for LPT-CBD for Chronic Pain May. 21 MT
Innocan Pharma Corporation Reports Breakthrough in a Pre-Clinical Trial: Liposomal-CBD Injection Restores Mobility to an Amputee Female Donkey May. 09 CI
InnoCan Pharma Corporation Initiates FDA Approval Process for Liposome Injection Therapy for Chronic Pain Apr. 22 CI
InnoCan Pharma Corporation Reports Earnings Results for the Full Year Ended December 31, 2023 Apr. 01 CI
InnoCan Pharma Corporation Auditor Raises 'Going Concern' Doubt Mar. 31 CI
Innocan Pharma Corporation Announces the Signing of an Agreement with the Hebrew University Mar. 25 CI
InnoCan Pharma "Paves Its Way" to LPT-CBD Chemistry, Manufacturing and Controls (CMC), "Key Milestones" for FDA Approval Mar. 25 MT

Chart InnoCan Pharma Corporation

Chart InnoCan Pharma Corporation
INNO: Dynamic Chart

Company Profile

Logo InnoCan Pharma Corporation
Innocan Pharma Corporation is an Israel-based company active in the pharmaceuticals and wellness sectors. In the pharmaceuticals sector, the Company aims to provide a safe, non-opioid chronic pain management solutions for both animals and humans. To achieve this aim, the Company developed a CBD-loaded liposome drug delivery platform with exact dosing, prolonged and controlled release of synthetic CBD for non-opioid pain management. In the wellness sector, the Company develops and markets a wide portfolio of high-performance self-care and beauty products to promote a healthier lifestyle. Under this segment Innocan established a Joint Venture (BI Sky Global Ltd.) that focused on advanced, targeted online sales.
Employees
0
Sector
Pharmaceuticals
Calendar
2025-03-26 - Q4 2024 Earnings Release (Projected)
More about the company

Income Statement and Estimates

income-statement-evolution-chart INNOCAN-PHARMA-CORPORATIO More financial data
  1. Stock Market
  2. Equities
  3. INNO Stock
  4. News InnoCan Pharma Corporation
  5. Innocan Pharma Corp Brief: Citing US$1.3 Million Increase in Revenues Compared to Q1 2022